Stockscreener 앱 받기
18.62
4.05%
-0.77
시간 외 거래:
18.64
0.02
+0.11%
전일 마감가:
$19.39
열려 있는:
$19.01
하루 거래량:
2.15M
Relative Volume:
1.26
시가총액:
$2.96B
수익:
$1.27M
순이익/손실:
$-512.54M
주가수익비율:
-6.2713
EPS:
-2.9691
순현금흐름:
$-422.10M
1주 성능:
-5.17%
1개월 성능:
-14.18%
6개월 성능:
+6.68%
1년 성능:
+31.39%
1일 변동 폭
$18.50
$19.37
1주일 범위
$18.50
$20.55
52주 변동 폭
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.62 | 3.08B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI) - Stock Titan
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate - BioSpace
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Denali Therapeutics stock (US24823R1077): Takeda exits DNL593 partnership - AD HOC NEWS
Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating - Moomoo
Number of shareholders of Denali Therapeutics Inc. – SWB:4DN - TradingView
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
MSN Money - MSN
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali Therapeutics stock (US24823R1077): FDA priority review for Hunter syndrome drug - AD HOC NEWS
A Look At Denali Therapeutics (DNLI) Valuation After Accelerated FDA Approval Of AVLAYAH - Sahm
Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40 - Moomoo
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says - Moomoo
TradingKey - TradingKey
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating - Moomoo
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - Moomoo
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects - Eastern Progress
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA-approved Hunter syndrome drug reaches first U.S. patients - Stock Titan
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics (DNLI) wins FDA nod for AVLAYAH and ends Q1 2026 with $1.05B cash - Stock Titan
Press Release: Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This - Benzinga
FMR LLC increases visibility on Denali (DNLI): 6.67M shares disclosed - Stock Titan
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out' - Sahm
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - AOL.com
Assessing Denali Therapeutics (DNLI) Valuation After Takeda Ends DNL593 Partnership - Sahm
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - Yahoo Finance
D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform - Seeking Alpha
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive? - Yahoo Finance
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.1%What's Next? - MarketBeat
Denali Therapeutics Reclaims DNL593 Rights After Takeda Collaboration Ends - HarianBasis.co
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in - Yahoo Finance
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Denali gains on FDA approval of lead asset - MSN
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.25%
자본화:
|
볼륨(24시간):